Interim Results
20 November 2008
London, UK, Brentwood, TN, 20 November 2008 - Protherics PLC (“Protherics” or the “Company”), the biopharmaceutical company focused on critical care and cancer, today announces its unaudited interim results for the six months ended 30 September 2008.
More Information
Voraxaze™ rolling BLA submission initiated with the US FDA
20 November 2008
London, UK; Brentwood, TN, US; 20 November 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that it has commenced the submission of a rolling Biologics License Application (BLA) for Voraxaze with the Food and Drug Administration (FDA) in the US. This marketing application is being made for the interventional use of Voraxaze for the rapid and sustained reduction of methotrexate (MTX) in patients who have toxic MTX levels due to impaired renal function.
More Information
Proposed delisting of American Depositary Shares from NASDAQ
14 November 2008
London, UK; Brentwood, TN, US; 14 November 2008 - Protherics PLC (LSE: PTI, Nasdaq: PTIL) (“Protherics”) has today provided notice to NASDAQ for the delisting of its American Depositary Shares (“ADSs”) in connection with its proposed acquisition by BTG plc (“BTG”), a public limited company incorporated under the laws of England and Wales with ordinary shares listed on the London Stock Exchange (LSE: BGC).
More Information
Additional “DEEP” study analyses and new mechanistic data presented at major conference
24 September 2008
London, UK; Brentwood, TN, US; 24 September 2008 - Protherics PLC (“Protherics” or the “Company”) the international biopharmaceutical company focused on critical care and cancer, today reports the findings of further analyses of data from its placebo-controlled phase 2b Digibind® (GSK) Efficacy Evaluation in Pre-eclampsia (“DEEP”) study. These new analyses, together with results from a mechanistic study, were presented in two oral presentations at the 16th World Congress of The International Society for the Study of Hypertension in Pregnancy (ISSHP) in Washington DC, US this week.
More Information
Protherics announces a proposed merger with BTG through a recommended share offer
18 September 2008
Please click on the link below to access this news release.
More Information
Start of Prolarix™ phase 2 study in liver cancer
27 August 2008
London, UK; Brentwood, TN, US; 27 August 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces the initiation of a phase 2a proof-of-concept study of Prolarix™, a targeted prodrug chemotherapy being developed for the treatment of primary liver cancer (hepatocellular carcinoma or “HCC”). This follows promising data from a phase 1 study of Prolarix, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA on 2 June 2008.
More Information
Re share price rise
13 August 2008
London, UK; Brentwood, TN, US; 13 August 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, notes today’s rise in the Company’s share price and confirms it has received approaches from a number of parties interested in acquiring Protherics, which the board is considering. However, there can be no certainty that any formal offer will be made, nor as to the terms on which any offer might be made.
More Information
DEEP results in pre-eclampsia to be presented at leading conference
6 August 2008
London, UK; Brentwood, TN, US; 6 August 2008 – Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that data from the “DEEP” study has been selected as one of the key presentations at the 16th World Congress of The International Society for the Study of Hypertension in Pregnancy (ISSHP) in Washington DC, US 21-25 September 2008.
More Information
AGM and Interim Management Statement
22 July 2008
London, UK; Brentwood, TN, US; 22 July 2008 – Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today provides its Interim Management Statement for the period 31 March to 21 July 2008. This statement summarises comments to be made today by Stuart Wallis, Chairman of Protherics’ at the Annual General Meeting at midday today.
More Information
Start of phase 2a clinical study of Angiotensin Therapeutic Vaccine in hypertension
24 June 2008
London, UK; Brentwood, TN, US; 24 June 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that the first patient has been enrolled in a phase 2a study of its Angiotensin Therapeutic Vaccine (ATV) for the treatment of hypertension.
More Information
Preliminary Results for the 12 months ended 31 March 2008
3 June 2008
London, UK, Brentwood, TN, 3 June 2008 - Protherics PLC, (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces its preliminary results for the 12 months ended 31 March 2008.
More information
Prolarix™ phase 1 data to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
2 June 2008
London, UK; Brentwood, TN, US; 2 June 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that preliminary results of a phase 1 clinical study of Prolarix™ will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA, at 12 midday local time on Monday 2 June. The clinical study was conducted by Cancer Research UK and Dr. Debashis Sarker of the Royal Marsden Hospital, London will be presenting.
More Information
Results from phase 2b “DEEP” study in severe pre-eclampsia
22 April 2008
London, UK; Brentwood, TN, US; 22 April 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that its placebo-controlled phase 2b Digoxin Immune Fab (DIF) Efficacy Evaluation in Pre-eclampsia (“DEEP”) study in severe pre-eclampsia has met one of its two primary endpoints. Severe pre-eclampsia is a potentially life threatening complication of pregnancy for which there is no effective treatment other than delivery of the baby. Pre-eclampsia is a leading cause of maternal and infant death throughout the world.
More Information
Interim Management Statement
14 February 2008
London, UK; Brentwood, TN, US; 14 February 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today provides its Interim Management Statement for the quarter ended 31 December 2007.
More Information
Start of OncoGel™ Phase 2b Study in Oesophageal Cancer
24 January 2008
London, UK; Brentwood, TN, US; 24 January 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that the first patient has now been enrolled in a phase 2b study of OncoGel™ in oesophageal cancer. OncoGel™ is a novel locally-administered sustained-release formulation of paclitaxel, an established chemotherapeutic agent for the treatment of solid tumours.
More Information
Start of CytoFab™ Phase 2 Programme in Severe Sepsis
22 January 2008
London, UK; Brentwood, TN, US; 22 January 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that AstraZeneca has treated the first patient in its expanded phase 2 programme of CytoFab™ in severe sepsis, an inflammatory condition resulting from uncontrolled infections.
More Information
Protherics and Advancell start Acadra™ clinical study in B-cell chronic lymphocytic leukaemia
11 January 2008
London, UK; Brentwood, TN, US; 11 January 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, and its co-development partner, Advancell s.l. (“Advancell”), today announce that the first patient has now been enrolled in a recently initiated phase 1/2 clinical study of Acadra™ (acadesine) in B-cell chronic lymphocytic leukaemia (B-CLL).
More information
|